Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
TEEBACIN vs CAPREOMYCIN SULFATE
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
TEEBACIN is a combination of isoniazid and rifampin. Isoniazid inhibits mycolic acid synthesis in mycobacterial cell wall, while rifampin inhibits bacterial DNA-dependent RNA polymerase.
Inhibits bacterial protein synthesis by binding to the 30S ribosomal subunit, causing misreading of m RNA and inhibiting translation initiation. Also alters membrane permeability.
Treatment of tuberculosis (first-line therapy in combination with other antituberculosis agents)
Treatment of pulmonary tuberculosis as part of combination therapy,Salvage therapy for multidrug-resistant tuberculosis
1350 mg orally twice daily with food.
15 mg/kg (up to 1 g) intramuscularly or intravenously once daily for 60 days, then 15 mg/kg (up to 1 g) 2-3 times weekly for 12-18 months in combination with other antituberculosis agents.
Terminal elimination half-life is 2-4 hours in patients with normal renal function; clinical context: reduced dosing interval required in renal impairment (e.g., every 12-24 hours for Cr Cl <30 m L/min)
Terminal elimination half-life: 24-40 hours (prolonged in renal impairment; anuria may extend to 96-120 hours).
Isoniazid is metabolized primarily by N-acetyltransferase 2 (NAT2) in the liver. Rifampin is metabolized via deacetylation and undergoes extensive enterohepatic circulation; it is a potent inducer of CYP3A4 and other CYP450 enzymes.
Not significantly metabolized; primarily excreted unchanged in urine via glomerular filtration.
Primarily renal (80-90% as unchanged drug); minor biliary/fecal elimination (10-20%)
Primarily renal (80-90% as unchanged drug via glomerular filtration). Biliary/fecal elimination: <1%.
10-20% bound, primarily to albumin
Approximately 30% bound to serum proteins (albumin).
0.2-0.3 L/kg, indicating distribution primarily into extracellular fluid
0.4-0.6 L/kg (suggests distribution primarily into extracellular fluid; poor CNS penetration unless meninges inflamed).
Oral: 75-90%; bioavailability decreases with food intake
IM: 100% (only IM route available; no oral formulation).
GFR ≥60 m L/min: no adjustment; GFR 30-59: 1350 mg once daily; GFR 15-29: 1350 mg every 48 hours; GFR <15 or dialysis: not recommended.
Cr Cl 50-80 m L/min: 15 mg/kg every 24-36 hours; Cr Cl 30-50 m L/min: 15 mg/kg every 48 hours; Cr Cl 10-30 m L/min: 15 mg/kg every 72 hours; Cr Cl <10 m L/min: 15 mg/kg every 96-120 hours.
Child-Pugh A: no adjustment; Child-Pugh B: 1350 mg once daily; Child-Pugh C: not recommended.
No dose adjustment required for hepatic impairment; monitor for hepatotoxicity.
Not established; safety and efficacy not evaluated.
15-30 mg/kg intramuscularly or intravenously once daily (maximum 1 g) for 60 days, then 15-30 mg/kg 2-3 times weekly (maximum 1 g).
Start at 1350 mg once daily; monitor renal function; increase to twice daily if tolerated and Cr Cl ≥60 m L/min.
Initiate at lower end of dosing range; adjust based on renal function due to age-related decline in glomerular filtration rate.
Severe and sometimes fatal hepatitis has been reported with isoniazid. Risk is increased in patients with pre-existing liver disease, daily alcohol use, or concurrent use of other hepatotoxic drugs.
None officially listed by FDA; however, use with caution due to potential nephrotoxicity and ototoxicity.
Hepatotoxicity (monitor liver function); peripheral neuropathy (pyridoxine supplementation recommended); hypersensitivity reactions; rifampin may cause reddish discoloration of body fluids; drug interactions due to CYP450 induction.
Nephrotoxicity: Monitor renal function; risk increases with cumulative dose and concomitant nephrotoxic drugs.,Ototoxicity: Can cause vestibular and cochlear damage, especially in patients with renal impairment.,Neuromuscular blockade: May exacerbate weakness in patients with myasthenia gravis or other neuromuscular disorders.,Electrolyte disturbances: Hypokalemia, hypocalcemia, and hypomagnesemia due to renal tubular effects.
Hypersensitivity to isoniazid, rifampin, or any component; severe hepatic damage; acute liver disease; history of isoniazid-associated hepatotoxicity.
Hypersensitivity to capreomycin or any component,Pre-existing severe renal impairment (Cr Cl < 30 m L/min) unless benefit outweighs risk,Pre-existing hearing loss
Avoid high-tyramine foods (aged cheeses, cured meats, fermented products) as it may cause hypertensive crisis. Take with food to reduce gastrointestinal upset. Avoid tyramine-rich foods like soy products and sauerkraut.
No specific food interactions. However, maintain adequate hydration and electrolyte-rich diet (bananas, potatoes) to mitigate hypokalemia.
TEEBACIN is contraindicated in pregnancy. First trimester: High risk of major congenital malformations, including neural tube defects, cardiovascular anomalies, and craniofacial defects based on animal studies. Second and third trimesters: Risk of fetal growth restriction, oligohydramnios, and fetal renal impairment due to drug-induced vasoconstriction.
Animal studies suggest embryotoxicity and teratogenicity; human data limited. Avoid in first trimester; use in second and third trimesters only if clearly needed. Risk of ototoxicity and nephrotoxicity to fetus.
Unknown if TEEBACIN is excreted in human milk. Due to potential for serious adverse reactions in nursing infants, including immunosuppression and growth retardation, breastfeeding is not recommended. M/P ratio not available.
Small amounts excreted in breast milk; not expected to cause adverse effects in infants due to poor oral absorption. M/P ratio unknown.
No dosing recommendations for use in pregnancy as drug is contraindicated. If used inadvertently, pharmacokinetic changes include increased renal clearance in later pregnancy, which may reduce drug exposure. However, due to teratogenicity, no dose adjustment is advised; immediate discontinuation upon pregnancy detection is recommended.
No dose adjustment recommended for pregnancy alone; however, concurrent use may require monitoring and adjustment. No pharmacokinetic changes reported.
Monitor liver function tests (ALT, AST) monthly due to risk of hepatotoxicity. Avoid use in patients with porphyria as it may precipitate acute attacks. Contraindicated in pregnancy (Pregnancy Category X). Administer with pyridoxine (vitamin B6) to reduce peripheral neuropathy risk.
Capreomycin is a second-line injectable agent for multidrug-resistant tuberculosis (MDR-TB). Monitor for nephrotoxicity (creatinine, BUN) and ototoxicity (audiometry, vestibular testing). Electrolyte disturbances (hypokalemia, hypomagnesemia) are common; replace aggressively. Administer deep IM injection; rotate sites. Contraindicated in pregnancy (teratogenic). Synergistic with other antituberculars; never use as monotherapy.
Take this medication exactly as prescribed; do not skip doses or stop early without consulting your doctor.,Avoid alcohol completely while taking this drug due to increased risk of liver damage.,Report any signs of liver problems: yellowing of skin or eyes, dark urine, severe nausea/vomiting, or abdominal pain.,Use effective contraception if you are of childbearing age; this drug can cause severe birth defects.,Take vitamin B6 supplements as directed to help prevent numbness or tingling in hands and feet.
Take exactly as prescribed; do not skip doses to prevent resistance.,Report hearing loss, ringing in ears, or dizziness immediately.,Report decreased urine output, swelling, or unusual fatigue.,You will need regular blood tests (kidney function, electrolyte levels).,Avoid alcohol and excessive salt intake.,Contact your doctor if you develop severe injection site pain or fever.
No interactions on record
"Decamethonium, a depolarizing neuromuscular blocker, and capreomycin, an aminoglycoside antibiotic, synergistically prolong neuromuscular blockade. Capreomycin decreases acetylcholine release at the motor endplate, while decamethonium persistently depolarizes the postsynaptic membrane, leading to enhanced and prolonged muscle relaxation. This interaction can result in extended respiratory depression and apnea, particularly during anesthesia or in critically ill patients."
"Streptozocin, a nitrosourea alkylating agent, may potentiate the neuromuscular blocking effects of capreomycin, a cyclic polypeptide antibiotic that inhibits neuromuscular transmission by reducing acetylcholine release at the motor endplate. This interaction can lead to prolonged or enhanced muscle weakness, including respiratory depression, particularly in patients with underlying neuromuscular disorders (e.g., myasthenia gravis) or those receiving other neuromuscular blocking agents. The clinical outcome may range from mild skeletal muscle weakness to severe respiratory compromise requiring mechanical ventilation."
"Paromomycin, an aminoglycoside antibiotic, and capreomycin, a polypeptide antibiotic, both possess neuromuscular blocking properties. Their co-administration can result in additive or synergistic neuromuscular blockade, potentially leading to prolonged or enhanced muscle relaxation, respiratory depression, or apnea. This interaction is particularly dangerous in patients receiving general anesthetics, neuromuscular blocking agents, or those with underlying neuromuscular disorders such as myasthenia gravis."
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about TEEBACIN vs CAPREOMYCIN SULFATE, answered by our medical review team.
TEEBACIN is a Antitubercular agent that works by TEEBACIN is a combination of isoniazid and rifampin. Isoniazid inhibits mycolic acid synthesis in mycobacterial cell wall, while rifampin inhibits bacterial DNA-dependent RNA polymerase.. CAPREOMYCIN SULFATE is a Antitubercular Agent that works by Inhibits bacterial protein synthesis by binding to the 30S ribosomal subunit, causing misreading of m RNA and inhibiting translation initiation. Also alters membrane permeability.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between TEEBACIN and CAPREOMYCIN SULFATE depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of TEEBACIN is: 1350 mg orally twice daily with food.. The standard adult dose of CAPREOMYCIN SULFATE is: 15 mg/kg (up to 1 g) intramuscularly or intravenously once daily for 60 days, then 15 mg/kg (up to 1 g) 2-3 times weekly for 12-18 months in combination with other antituberculosis agents.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between TEEBACIN and CAPREOMYCIN SULFATE in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. TEEBACIN is classified as Category C. TEEBACIN is contraindicated in pregnancy. First trimester: High risk of major congenital malformations, including neural tube defects, cardiovascular anomalies, and craniofacial de. CAPREOMYCIN SULFATE is classified as Category C. Animal studies suggest embryotoxicity and teratogenicity; human data limited. Avoid in first trimester; use in second and third trimesters only if clearly needed. Risk of ototoxici. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.